Prelude Therapeutics
PRLD | NASDAQ
$3.41
-$0.04 (-1.16%)
At close: Nov 16, 2026, 4:00 PM ET
$3.41
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
-1.16%
(1D)No price chart data available for 1D timeframe.
Rating
55.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #182/1021 (Top 18%)
Key Statistics
Market Data
Market Cap $335.51M
1D Range
3.28 3.46
52W Range
1.35 6.63
Valuation (TTM)
PE -4.32
PB 2.51
EV/EBITDA -3.42
Valuation (NTM)
Forward PE 34.64
Forward PEG 0.06
Price Target $8.00
Cash Flow
FCF Yield -9.9%
SBC Adj. FCF Yield -12.4%
SBC Impact -24.9%
Margins
Gross Margin 98.3%
Operating Margin -300.6%
FCF Margin -148.3%
Growth (CAGR)
Revenue 3Y | 5Y 114.3% |
88.1%
Dil EPS 3Y | 5Y 36.1% |
22.2%
FCF 3Y | 5Y 44.2% |
12.4%
Returns
ROA -31.9%
ROE -75.3%
ROIC -43.7%
Financial Health
Net Cash
$148.98M
Current Ratio 4.07
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs....
Sector Healthcare
Industry Biotechnology
Employees 79
IPO Date Sep 25, 2020
Website www.preludetx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 16, 2026
EPS
-$0.12
Miss -1300.00%
YoY:
+53.85% REV
$5.65M
Miss -80.53%
YoY:
-13.12%Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$8.00
Upside
+134.60%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PRLD